RT Journal Article
SR Electronic
T1 Does the Addition of Abiraterone to Castration Affect the Reduction in Bone Mineral Density?
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 3291
OP 3299
DO 10.21873/invivo.12167
VO 34
IS 6
A1 SHIORI NAKAJIMA
A1 TAKAMITSU INOUE
A1 MINGGUO HUANG
A1 KOICHIRO TAKAYAMA
A1 SOKI KASHIMA
A1 RYOHEI YAMAMOTO
A1 ATSUSHI KOIZUMI
A1 TAKETOSHI NARA
A1 KAZUYUKI NUMAKURA
A1 MITSURU SAITO
A1 SHINTARO NARITA
A1 MASATOMO MIURA
A1 SHIGERU SATOH
A1 TOMONORI HABUCHI
YR 2020
UL http://iv.iiarjournals.org/content/34/6/3291.abstract
AB Background/Aim: The in vivo effect of abiraterone on bone mineral density (BMD) in addition to androgen deprivation therapy was examined using a murine model. Materials and Methods: The mice were separated into the following groups: control, abiraterone, castration, and castration+abiraterone. The percentage change in the ratio of bone to tissue volume (BV/TV), number of osteoblasts and osteoclasts, and the serum level of bone markers were compared on day 21. Results: The BV/TV ratio of the abiraterone, castration, and castration+abiraterone groups was lower than that of the control group. However, the change in the BV/TV ratio in the castration+abiraterone group was not significantly different from that in the castration group. There was no significant difference in the serum TRAP5b level and the number of osteoclasts and osteoblasts between the castration+abiraterone and the castration groups. Conclusion: The addition of abiraterone to castration did not affect BMD in the murine model.